Navigation Links
Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Date:11/19/2008

MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI) today announced that it has submitted, and that the FDA has received its application for 510(k) clearance for its HAPTOCHEK(TM) diagnostic test kit. The 510(k) submission begins a 90-day review process, during which the FDA will determine whether the kit can be distributed to labs throughout the country as an in vitro diagnostic.

"We are very pleased to announce the submission of a 510(k) application for our test kit to the FDA, as it demonstrates that we are continuing to execute on our business plan," said Noah Berkowitz, M.D., President and CEO of Synvista Therapeutics. "We believe that, once cleared by the FDA, our test will become an important facilitator of personalized medicine and may provide a standard by which physicians can influence clinical outcome."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical diagnostic laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical laboratory test to identify patients with Hp2-2 diabetes. Tests which identify patients with Hp2-2 diabetes may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endprodu
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... LESS Instrumentation Is Selected for Industry Leader LESS Panel ... 29 Cambridge Endo, a pioneer in the rapidly ... or SPA) market, is pleased to announce that its ... leaders selected to be on a LESS panel at ...
... Laboratory InstrumentsMENLO PARK, Calif. and NORWOOD, Mass., Jan. ... today jointly announced that Advanced Instruments Inc. has ... The two companies further announced their intention ... generation of laboratory instruments for osmolality measurement, incorporating ...
... N.J., Jan. 29 Amicus Therapeutics (Nasdaq: ... 2008 financial results after the regular close of markets ... be followed by a live conference call and webcast ... investors may access the conference call at 5 p.m. ...
Cached Biology Technology:Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009 2Advanced Instruments Makes Strategic Investment in Cantimer, Inc. 2Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:7/28/2014)... ago, MIT professor John Essigmann and colleagues from the University ... They thought if they could induce the virus to mutate ... out a strategy that our immune system uses against ... which caused HIV to mutate at an enhanced rate, as ... in a small clinical trial reported in 2011. In a ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... MANHATTAN, Kansas He calls himself the bug hunter, ... that can only be found and identified with special ... at the Kansas State Veterinary Diagnostic Laboratory at Kansas ... his discoveries, porcine enterovirus G, which is an important ... a virus in cells, but didn,t know what it ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... CORVALLIS, Ore. Researchers at Oregon State University ... the collapse of oyster seed production at a commercial ... to a level considered by the owners to be ... that elevated seawater carbon dioxide (CO2) levels, resulting in ...
... Mass. Copper the stuff of pennies and tea ... can turn carbon dioxide into hydrocarbon fuels with relatively little ... copper acts as a strong catalyst, setting off an electrochemical ... methane or methanol. Various researchers around the world have ...
... CO, USA -- April 10, 2012 -- HUNT Biosciences ... advance the clinical use of protein biomarkers, with an ... prediction of cardiovascular events such as strokes, heart attacks, ... samples and clinical data from HUNT Biosciences using SomaLogic,s ...
Cached Biology News:Ocean acidification linked to larval oyster failure 2Ocean acidification linked to larval oyster failure 3Hybrid copper-gold nanoparticles convert CO2 2Hybrid copper-gold nanoparticles convert CO2 3
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from within ... FANCM. (Note: the amino acid sequence ... as ab27787 .) ...
Biology Products: